MLYS Mineralys Therapeutics, Inc. Insider Trading

CMO David Malcom Rodman sells 20,407 shares for $556,671.34 at unprofitable MLYS; 10b5-1 plan; retains 51,384 shares plus stock options

David Malcom Rodman, Chief Medical Officer, executed 2 separate sales totaling 20,407 shares for $556,671.34 on 2026-07-13 and 2026-07-15, reducing his non-derivative holdings by -28.4% to 51,384 shares. This transaction is scheduled under a 10b5-1 trading plan adopted on 2025-10-06, not discretionary. The company is unprofitable with net income of $-39,339,000.00 over its most recent full fiscal year. His prior sales at this ticker show mixed short-term outcomes: the most recent measurable same-ticker sale on 2026-04-13 returned +1.2% over 30 days and +6.9% over 90 days, while his cross-ticker track record across 20 prior sells averages -8.9% over 30 days and -10.8% over 90 days. The stock trades -42.7% below its 52-week high of $47.65, though it has gained 14.2% over the past 30 days. Rodman retains significant derivative holdings through stock options totaling 109,792 and 79,167 shares across two vehicles.

CEO Jon Congleton sold 75,000 shares for $1,960,601.40 via pre-arranged 10b5-1 plan at MLYS on 2026-06-30

Jon Congleton, CEO of Mineralys Therapeutics, executed 2 sales totaling 75,000 shares (75.0K shares) for $1,960,601.40 on 2026-06-30 at blended average price $26.14, reducing his holdings by 10.9% to 614,321 shares. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-30 and therefore scheduled rather than discretionary. The stock currently trades at $26.98, down 43.4% from its 52-week high of $47.65, and has declined 14.4% over the prior 30 days. The company reported negative net income of $-39,339,000.00 for the most recent full fiscal year. His prior 5 trades at MLYS show mixed subsequent performance, with 30-day and 90-day returns ranging from +4.5% to -10.2%, providing no clear directional pattern at this specific ticker.

Chief Commercial Officer Eric Warren sold 104,124 shares of MLYS at $25.90 via 10b5-1 plan adopted 2026-03-27; retains 38,400 shares plus 252,876 stock options.

Eric Warren, Chief Commercial Officer, executed a scheduled sale of 104,124 shares for $2,696,322.22 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-27—this is a non-discretionary, planned transaction. His non-derivative holdings fell to 38,400 shares from 142,524 shares, but he retains 252,876 stock options in derivative form, maintaining material exposure to the company. The sale occurred at $25.90, and the stock currently trades at $26.98, down -43.4% from its 52-week high of $47.65; this timing reflects the plan's adoption date (March 2026), not active market timing. Most critically, the company reported a full-year net income of -$39,339,000.00, indicating sustained unprofitability during the period leading up to plan adoption, which provides context for when this scheduled liquidation was locked in.

CMO Rodman Malcom sold $652.6K in MLYS shares while stock trades 44% below 52-week high; eighth sale at this ticker in 36 months.

Rodman Malcom, Chief Medical Officer, disposed of approximately 22,500 shares across three transactions on consecutive trading days, reducing his direct stake from roughly 70,000 shares to 63,000. This is his eighth open-market sale at Mineralys in the past two years—a clear pattern of consistent equity reduction with no offsetting purchases. The stock currently trades well below its 52-week high, having declined over a longer stretch, yet Malcom's prior five sales at this ticker show mixed near-term timing (two well-timed exits, three where the stock subsequently climbed) but uniformly poor timing at the 90-day horizon, with every prior sale followed by stock gains. The company remains unprofitable with ongoing quarterly losses, presenting a backdrop of fundamental weakness during which the CMO is further lightening his exposure. This filing represents a continuation of the insider's singular focus on exits—he has never made an open-market purchase at Mineralys—suggesting persistent conviction to reduce shares rather than reposition for recovery.

CMO David Malcom sold 20,406 shares at $26.54–$27.66 for $548,672.35 on two dates in April 2026.

Rodman David Malcom, Chief Medical Officer at Mineralys Therapeutics, executed 2 separate sales totaling 20,406 shares for $548,672.35 (blended average $26.89), reducing his post-transaction holdings to 69,792 shares from 90,198 shares (a 22.6% reduction). The company remains unprofitable, with net income of $-36,932,000.00 over the most recent full fiscal year. While Malcom's cross-ticker track record shows strong timing accuracy (100.00% well-timed rate across 20 prior sells), his same-ticker history at MLYS shows mixed recent outcomes: 5 prior trades exhibited returns of +2.7%, -4.3%, -2.7%, -2.7%, and -4.2% at the 30-day mark, with 0 of these prior sells well-timed at the 90-day horizon. The current stock price of $30.42 is 18.2% above the 30-day moving average but 35.7% below the 52-week high of $47.33, placing the sale prices ($26.54–$27.66) materially below current valuation and below the historical peak.

CEO Congleton Jon sells 75,000 shares at blended average $26.27 under pre-arranged 10b5-1 plan

Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, executed 3 separate sales on 2026-03-31 totaling 75,000 shares for $1,970,521.82 at prices ranging from $25.50 to $27.05. This transaction was conducted under a 10b5-1 trading plan adopted 2025-12-30, meaning it was scheduled and non-discretionary. His post-transaction holdings of 705,051 shares represent a 9.6% reduction from pre-transaction levels of 780,051 shares. As a pre-arranged plan execution, this sale reflects previously scheduled timing rather than a discretionary response to current market conditions.

RA Capital Management (Director) buys 369,000 shares for $8.8M at $23.75 avg; stock now $27.09, down 25.4% in 90 days.

RA Capital Management, L.P. executed 2 separate purchases totaling 369,000 shares for $8,762,797.00 (blended average $23.75 per share) on March 27 and March 30, 2026, increasing holdings by 6.8% to 5,825,521 shares post-transaction. The buyer's cross-ticker track record shows strong prior buy performance with average 90-day returns of +69.8% and a 100% win rate across 13 prior open-market purchases, though Mineralys specifically shows a recent 90-day decline of -25.4% from the transaction window, substantially exceeding the broader market weakness. The company posted a full-year net income of $-36,932,000.00, operating unprofitably; the $8.8M deployment into an unprofitable biotech at a 6.8% portfolio increase by a major director-level holder warrants attention to whether this reflects conviction in near-term recovery or pipeline inflection versus defensive positioning in a distressed position.

CMO David Rodman sold 20,406 shares for $542,973.38 across 4 sales on 2026-03-12/13 under pre-arranged 10b5-1 plan

Rodman David Malcom, Chief Medical Officer, executed 4 separate sales totaling 20,406 shares for $542,973.38 on March 12–13, 2026, at prices ranging from $25.91 to $27.82 per share. This transaction reduced his holdings by 21.1% from 96,546 shares to 76,140 shares. Because this sale is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-10-06, it was scheduled rather than discretionary and thus carries no timing signal. The multi-transaction structure and modest post-sale holdings suggest routine portfolio management rather than a major exit.

CMO Rodman David Malcom sold 20,404 shares for $569.8K via pre-arranged 10b5-1 plan

Rodman David Malkom, Chief Medical Officer of Mineralys Therapeutics, executed 5 separate sales totaling 20,404 shares for $569,809.06 between February 12-13, 2026, at a blended average price of $27.93. The sales occurred across two trading days at prices ranging from $27.33 to $29.64 per share. Post-transaction holdings of 44,089 shares represent a 31.6% reduction from pre-transaction holdings of 64,493 shares. This activity is part of a pre-arranged 10b5-1 trading plan adopted on 2025-10-06, meaning the transactions were scheduled in advance rather than discretionary decisions made in response to market conditions. As a scheduled divestiture under an established plan, this transaction reflects pre-determined execution rather than an opportunistic market signal.

CMO Rodman David Malcom sold 19,076 shares at $32.66–$32.75 for $623,114.66 under pre-arranged 10b5-1 plan.

Rodman David Malcom, Chief Medical Officer, executed 2 separate sales totaling 19,076 shares for $623,114.66 on 2026-01-13 and 2026-01-14, reducing holdings by 27.4% from 69,513 to 50,437 shares. The transactions are part of a pre-arranged 10b5-1 trading plan adopted on 2025-10-06, indicating scheduled, non-discretionary execution rather than a response to current market conditions. The blended average sale price of $32.66 represents the execution price of the plan as scheduled. This filing reflects mechanical portfolio management under a pre-existing framework and does not reveal discretionary trading signals.